Plant · Scientific monograph
Andrographis paniculata
King of Bitters / Green Chiretta
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Immunostimulant Research, Anti-infective Research, Anti-inflammatory Research, Upper Respiratory Research
Research overview
Historical use
Andrographis paniculata (known as kalmegh in Ayurveda, chuan xin lian in traditional Chinese medicine) is native to South and Southeast Asia and has been used medicinally for over 2,000 years. Its intensely bitter taste (one of the most bitter medicinal plants known) led to the common name 'King of Bitters'. In Ayurvedic medicine it was prescribed for fever, liver disorders, intestinal complaints, and as an antidote to venoms. In traditional Chinese medicine it was classified as a heat-clearing, detoxifying herb used for infections, diarrhoea, and inflammatory conditions. During the 1919 influenza pandemic it was reportedly used in India to treat fever; during the COVID-19 pandemic it received renewed scientific attention for antiviral properties.
Modern research context
Andrographis paniculata has the strongest clinical evidence base among immunostimulant herbs for upper respiratory tract infections (URTIs). A 2021 pharmacoepidemiological analysis documented real-world utilisation of Andrographis paniculata for URTI management in clinical practice settings [1]; note that pharmacoepidemiology data describes prescribing patterns and does not substitute for RCT-based efficacy evidence — clinical efficacy is supported by the meta-analyses at [3] and [5]. A 2023 meta-analysis of RCTs found standardized andrographolide extract (SHA-10) significantly reduces symptom severity scores for uncomplicated URTI compared to placebo, with comparable efficacy to some antiviral agents [3]. A 2004 systematic review by Poolsup et al. found that Andrographis paniculata preparations significantly reduced URTI symptom scores compared to placebo across included RCTs, supporting Level B–A evidence for URTI symptom relief at doses of 200 mg andrographolide equivalent/day for 5–7 days [5]. Note: this is a peer-reviewed systematic review published in a pharmacy journal — not a Cochrane review. Anti-inflammatory effects in rheumatoid arthritis have been studied in RCTs with mixed results (Level C). Emerging evidence for antiviral activity against influenza, dengue, and SARS-CoV-2 in preclinical models; human trial data for antiviral indications beyond URTI remain Level C–D.
Adverse effects
The most common adverse effect is GI discomfort — nausea, diarrhoea, and stomach upset due to the intensely bitter andrographolide content. Rare case reports of hypersensitivity reactions including anaphylaxis following oral administration have been reported in post-marketing surveillance; see safety review PMID 34818697 for documented adverse event data. Lymphadenopathy and elevation of liver enzymes have been reported in case series with prolonged or high-dose use. Anti-fertility effects have been demonstrated in male animal models (reversible oligospermia in rodent studies; animal data only — not confirmed in human clinical trials) [citation for animal oligospermia data required]; clinical relevance in humans is uncertain but warrants precautionary avoidance in men trying to conceive. Headache and fatigue have been reported in clinical trials.
Contraindications
Male infertility concerns — animal studies show andrographolide-induced reversible oligospermia; avoid in men actively trying to conceive. Autoimmune disease — immunostimulant activity may exacerbate autoimmune conditions. Pre-surgery: withdraw at least 2 weeks prior — andrographolide has antiplatelet activity (inhibits platelet aggregation). Concurrent anticoagulant or antiplatelet therapy — enhanced bleeding risk. Known hypersensitivity to Andrographis or Acanthaceae family plants.
Clinical and phytochemical data
Used part
Aerial parts — leaves, stems, and branches (dried; standardized for andrographolide content). Some preparations also use root.
Primary active compounds
Andrographolide (diterpenoid lactone, ~0.5–2% of dry weight) — primary active; anti-inflammatory, antiviral, immunostimulant
14-Deoxy-11,12-didehydroandrographolide (dehydroandrographolide) — antiviral
Neoandrographolide (diterpenoid) — immunostimulant
Andropanolide, isoandrographolide (diterpenoids)
Arabinogalactan polysaccharides — immunostimulant
Flavonoids: andrographidine A–F, apigenin, luteolin
Xanthones: 8-methoxywogonin
Mechanism of action
Andrographolide is the dominant active compound with multiple pharmacological targets. Anti-inflammatory activity is mediated through covalent binding to and inhibition of NF-κB p50 subunit nuclear translocation, suppressing transcription of COX-2, iNOS, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) [4]. Immune stimulation involves activation of T-lymphocytes and natural killer (NK) cells, increased IL-2 production, and macrophage phagocytosis enhancement — the mechanism underlying URTI efficacy [1, 3]. Antiviral activity is attributed to inhibition of viral replication via blockade of NF-κB-dependent viral promoter activity and direct interference with viral entry (demonstrated for influenza A, dengue virus, and SARS-CoV-2 proteases in vitro). Andrographolide also activates Nrf2, upregulating antioxidant response elements. Anti-platelet aggregation occurs through inhibition of thromboxane A2 synthesis and PAF receptor antagonism.
Pharmacokinetics
Absorption
Human PK data available from pharmacokinetic studies of andrographolide. Oral bioavailability of andrographolide is approximately 20–30% from standardized extract; significantly lower for isolated pure compound due to poor aqueous solubility. Tmax approximately 1–2 hours after oral administration. Food moderately affects absorption. Formulation significantly impacts bioavailability — encapsulated standardized extract versus raw powder.
Distribution
Andrographolide distributes widely to tissues including liver, kidney, and lung (animal data). Plasma protein binding approximately 30–60%. CNS penetration has been reported in rodent studies. Volume of distribution data in humans not formally published.
Metabolism
Extensive hepatic metabolism via glucuronidation and sulfation. Several hydroxylated and glucuronide metabolites identified. Andrographolide undergoes rapid phase II conjugation, with metabolites excreted in urine and bile. CYP450 involvement in andrographolide metabolism is not fully characterised; CYP3A4 has been implicated in some metabolic pathways. No significant CYP induction reported at therapeutic doses.
Excretion
Renal excretion of andrographolide glucuronide and sulfate conjugates; biliary/fecal route also contributes. t1/2 of andrographolide approximately 6–10 hours. Due to rapid phase II conjugation, free andrographolide plasma levels decline quickly — multiple daily dosing is used in clinical trials.
Safety and interactions
Drug interactions
Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel, NSAIDs): andrographolide inhibits platelet aggregation via thromboxane A2 and PAF — clinically significant bleeding risk with concurrent anticoagulant use; monitor INR closely or avoid combination [4]. Immunosuppressants (cyclosporine, azathioprine, corticosteroids): immunostimulant activity may pharmacodynamically antagonise immunosuppressive therapy — avoid in transplant recipients. Antidiabetic medications: andrographolide has demonstrated hypoglycaemic activity in animal models; additive glucose-lowering effect possible — monitor blood glucose. ACE inhibitors: potential additive antihypertensive effects reported in vitro; clinical significance uncertain.
Toxicity
Andrographis paniculata preparations have been used extensively in Asia with a generally good safety record at standard doses (200 mg andrographolide equivalent/day for ≤7 days for URTI). Acute toxicity is low in animal studies. Reversible oligospermia observed in male rodents at high doses; human male reproductive toxicity is not confirmed but is a precautionary concern. Allergic reactions including anaphylaxis are rare but documented. Hepatotoxicity has been reported in isolated cases with prolonged or high-dose use; causal relationship not firmly established. Safety beyond 12 weeks is not established in controlled human trials.
Special precautions
Pregnancy
Not recommended during pregnancy. Andrographolide has demonstrated emmenagogue and potential abortifacient activity in animal uterine smooth muscle studies (animal data only; no controlled human reproductive safety data) [citation for animal uterotonic/abortifacient data required — search andrographolide uterotonic PubMed]. Several traditional medical systems explicitly contraindicate its use in pregnancy. Evidence basis: animal experimental data; traditional contraindication; no controlled human safety data.
Lactation
Insufficient safety data. Not recommended during breastfeeding. Andrographolide excretion in breast milk not studied.
Hepatic impairment
Case reports of liver enzyme elevation with prolonged use. No formal PK studies in hepatic impairment. Use with caution in hepatic disease; liver function monitoring recommended with use beyond 7 days.
Renal impairment
Andrographolide metabolites are renally excreted. No formal pharmacokinetic studies in renal impairment. Use with clinical monitoring in significant renal impairment.
Sources and references
- [1] - Nguyen T et al., "Andrographis paniculata for upper respiratory tract infection", Pharmacoepidemiol Drug Saf, 2021, PMID: 33372366
- [2] - Saxena RC et al., "A randomized double blind placebo controlled clinical evaluation of Andrographis paniculata extract in patients with acute upper respiratory tract infection", Phytomedicine, 2010 — cited in PMID: 28783743
- [3] - Okhuarobo A et al., "Meta-analysis of Andrographis paniculata for upper respiratory infection", Drug Discov Ther, 2023, PMID: 37821383
- [4] - Shang M et al., "Safety and efficacy review", Phytother Res, 2022, PMID: 34818697
- [5] - Poolsup N et al., "Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection", J Clin Pharm Ther, 2004, PMID: 14748896